Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 301 to 310 of 1338 total matches.
Tramadol - A New Oral Analgesic
The Medical Letter on Drugs and Therapeutics • Jul 07, 1995 (Issue 952)
Administration for oral
treatment of moderate to moderately severe pain. Despite some opioid activity, tramadol ...
Tramadol hydrochloride (Ultram - Ortho-McNeil), a centrally-acting analgesic marketed in Germany since 1977, was recently approved by the US Food and Drug Administration for oral treatment of moderate to moderately severe pain. Despite some opioid activity, tramadol has not been scheduled as a controlled substance.
Beta-Adrenergic Blockers and Breast Cancer
The Medical Letter on Drugs and Therapeutics • Jan 23, 2012 (Issue 1382)
. No
prospective, randomized trials have been published.1
MECHANISM OF ACTION — Activation of the betaadrenergic ...
Three retrospective studies have recently reported an
association between beta-blocker use and a reduction
in breast cancer metastasis and recurrence. No
prospective, randomized trials have been published.
Vismodegib (Erivedge) for Basal Cell Carcinoma
The Medical Letter on Drugs and Therapeutics • Jul 09, 2012 (Issue 1394)
pathway are thought to be the
cause of basal cell carcinoma.2 Vismodegib inhibits
the signaling activity ...
The FDA has approved vismodegib (vis moe deg´ ib;
Erivedge – Genentech), the first hedgehog (Hh) pathway
inhibitor, for oral treatment of metastatic basal cell
cancer, locally advanced basal cell carcinoma that has
recurred after surgery, or locally advanced basal cell
carcinoma in adults who are not candidates for surgery
or radiation.
Ciprofloxacin Otic Suspension (Otiprio) for Acute Otitis Externa
The Medical Letter on Drugs and Therapeutics • Aug 13, 2018 (Issue 1553)
concentrations achieved with topical therapy.5
Other topical antimicrobials that are active
against both ...
The FDA has approved a 6% otic suspension
formulation of the fluoroquinolone antibiotic
ciprofloxacin (Otiprio – Otonomy) for single-dose
treatment of acute otitis externa (swimmer's
ear) caused by Pseudomonas aeruginosa or
Staphylococcus aureus in patients ≥6 months old.
Otiprio was approved earlier for prophylaxis in
children with bilateral otitis media with effusion who
are undergoing tympanostomy tube placement.
Sulbactam/Durlobactam (Xacduro) for Acinetobacter Pneumonia
The Medical Letter on Drugs and Therapeutics • Nov 27, 2023 (Issue 1690)
- associated pneumonia caused by susceptible gram- negative organisms, including ABC.
ACTIVITY ― Sulbactam ...
The FDA has approved Xacduro (Innoviva), a
combination of the beta-lactam antibacterial
sulbactam and the beta-lactamase inhibitor
durlobactam, for IV treatment of adults with hospital-acquired
or ventilator-associated bacterial pneumonia
caused by susceptible isolates of Acinetobacter
baumannii-calcoaceticus complex (ABC).
Med Lett Drugs Ther. 2023 Nov 27;65(1690):189-90 doi:10.58347/tml.2023.1690c | Show Introduction Hide Introduction
Tovorafenib (Ojemda) for Pediatric Low-Grade Glioma (online only)
The Medical Letter on Drugs and Therapeutics • Jun 10, 2024 (Issue 1704)
glioma harboring an
activating RAF alteration is ongoing.
ADVERSE EFFECTS — In the FIREFLY-1 trial ...
Tovorafenib (Ojemda – Day One), a type II RAF kinase
inhibitor, has received accelerated approval from the
FDA for treatment of patients ≥6 months old with
relapsed or refractory pediatric low-grade glioma
harboring a BRAF fusion or rearrangement or a BRAF
V600 mutation. Tovorafenib is the first systemic
treatment to be approved in the US for pediatric
low-grade gliomas with BRAF fusions. Accelerated
approval of tovorafenib was based on response rates
and duration of response.
Med Lett Drugs Ther. 2024 Jun 10;66(1704):e97-8 doi:10.58347/tml.2024.1704f | Show Introduction Hide Introduction
Saxagliptin (Onglyza) for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Nov 02, 2009 (Issue 1324)
hrs (active metabolite)
Metabolism Hepatic by CYP3A4/5 to active metabolite
(half as potent ...
Saxagliptin (Onglyza - Bristol-Myers Squibb), the second oral dipeptidyl peptidase-4 (DPP-4) inhibitor to be marketed in the US, has been approved by the FDA for treatment of adults with type 2 diabetes.
Cefiderocol (Fetroja) - A New IV Cephalosporin for Complicated UTI
The Medical Letter on Drugs and Therapeutics • May 04, 2020 (Issue 1597)
stability against
beta-lactamases.4,5
SPECTRUM OF ACTIVITY — Cefiderocol has no clinically
relevant ...
The FDA has approved cefiderocol (Fetroja – Shionogi),
a new IV cephalosporin antibiotic, for treatment of
complicated urinary tract infections (UTI) caused by
susceptible gram-negative bacteria in adults who
have limited or no alternative treatment options.
Pharmaceutical Drug Overdose
Treatment Guidelines from The Medical Letter • Sep 01, 2006 (Issue 49)
pneumonia. Perforation of the esophagus,
laryngospasm and hypoxia can occur.
Activated charcoal (AC ...
Every pharmaceutical drug is a dose-dependent poison. This article describes the clinical presentation and treatment of some dangerous overdoses commonly reported in adults.
Timing of Remdesivir for COVID-19
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020 (Issue 1609)
analog that inhibits viral
replication by binding to RNA-dependent RNA
polymerase. It is active against ...
Remdesivir (Veklury – Gilead), an investigational
antiviral drug administered by IV infusion, is now
available through an FDA Emergency Use Authorization
(EUA) for treatment of COVID-19 in all hospitalized
patients. An earlier EUA limited use of the drug to
patients hospitalized with severe disease.